Brief: Median Technologies : Promising Results On The Use Of The IBiopsy® Platform
Sept 8 (Reuters) - MEDIAN TECHNOLOGIES SA ALMDT.PA :
* PROMISING RESULTS ON THE USE OF THE IBIOPSY® PLATFORM IN
THE
CONTEXT OF MEASURING THE ANTI-TUMOR IMMUNE RESPONSE
* ESTABLISHMENT OF A BIOMARKER DERIVED FROM CT IMAGING TO
CHARACTERIZE THE TUMOR MICROENVIRONMENT
* A BIOMARKER FOR IDENTIFYING PATIENTS RESPONDING TO
TREATMENT
BASED ON ANTI-TUMOR IMMUNITY OF CD8+ CELLS
Source text for Eikon: ID:nBw86fgRqa
Further company coverage: ALMDT.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Median Technologies SA
See all newsBrief: Median Technologies Forms Strategic Review Committee To Consider iCRO Separation, US Listing
France's Median Technologies H1 order backlog rises on demand from biopharmaceutical clients
Brief: Median Technologies H1 Revenue EUR 11.8 Million
Brief: Median Launches Eur 40 Mln Capital Raise To Fund Eyonis Rollout, Extend Runway To H1 2028
Brief: Median Technologies Reports FY Revenue EUR 23.5 Million